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Objective – Aspirin together with thienopyridine P2Y12 inhibitors, commonly clopidogrel, 
is a cornerstone of antiplatelet therapy. However, many patients receiving this therapy 
display high on-treatment platelet reactivity (HTPR) which is a major therapeutic hurdle 
to the prevention of recurrent thrombotic events. The emergence of uninhibited platelets 
following thrombopoiesis has been proposed as a contributing factor to HTPR. Here we 
investigate the influences of platelet turnover on platelet aggregation in the face of 
different dual antiplatelet therapy strategies. 
Approach and Results - Traditional light transmission aggregometry, cytometry, 
advanced flow cytometric imaging and confocal microscopy were used to follow the 
interactions of populations of platelets from healthy volunteers and patients with stable 
cardiovascular disease. Newly formed, reticulated platelets over-proportionately 
contributed to, and clustered at, the core of forming aggregates. This phenomenon was 
particularly observed in samples from patients treated with aspirin plus a thienopyridine, 
but was absent in samples taken from patients treated with aspirin plus ticagrelor.  
Conclusions- Reticulated platelets are more reactive than older platelets, and act as 
seeds for the formation of platelet aggregates even in the presence of antiplatelet 
therapy. This is coherent with the emergence of an uninhibited subpopulation of 
reticulated platelets during treatment with aspirin plus thienopyridine, explained by the 
short pharmacokinetic half-lives of these drugs. This phenomenon is absent during 
treatment with ticagrelor, due to its longer half-life and ability to act as a circulating 
inhibitor. These data highlight the importance influences of pharmacokinetics on anti-




























Platelets are central to the processes underlying atherothrombotic events and 
consequently are the target of well established prophylactic therapy.  The drug dosing 
regimen referred to as dual antiplatelet therapy (DAPT) typically comprises aspirin 
combined with a P2Y12 receptor antagonist, commonly the thienopyridine compound 
clopidogrel. 1-4 The reoccurrence of thrombotic events during therapy represents a 
major therapeutic hurdle and is associated with high on-treatment platelet reactivity 
(HTPR).3, 4 However, the causes of HTPR and thrombotic complications are complex 
and require deeper investigation to improve anti-thrombotic therapies.3-5 
 
One potential contributing factor to HTPR is an increased rate of platelet turnover. 
There are a notable number of pathological states linked to HTPR where platelet 
turnover and the circulating levels of newly formed immature platelets are increased. In 
particular, a recent study has associated elevated immature platelet counts, a measure 
of platelet turnover, with adverse cardiovascular outcomes.6 This relationship is clearly 
demonstrated in patients with chronic renal failure requiring haemodialysis whose 
reticulated platelet proportion increases threefold.7 Additionally there is a strong 
association between poor clopidogrel responsiveness and increased thrombotic risk.8, 9 
Nonetheless a pathophysiological mechanism has yet to be identified.  
 
Aspirin and clopidogrel, the most widely used P2Y12 receptor antagonist, irreversibly 
bind their respective targets, but are short-lived in the circulation. This suggests that as 
standard daily doses of either drug are quickly cleared newly formed platelets 
subsequently entering the circulation will remain uninhibited until the next dose is taken.  
We have recently demonstrated that uninhibited platelets can act as seeds for 
aggregate formation during antiplatelet therapy.10 Therefore, in patients with pathologies 
in which platelet production is increased larger subpopulations of these uninhibited 
platelets will arise. Compounding this, newly produced immature, or reticulated, 
platelets appear to be generally more reactive.11 
 
The more recently developed non-thienopyridine P2Y12 antagonist ticagrelor is, unlike 
thienopyridines, pharmacokinetically long-lived with a circulating half-life of about 8 
hours. With standard twice daily dosing it consistently circulates at inhibitory 
concentrations. Also unlike thienopyridines, ticagrelor acts directly as a reversibly-
binding antagonist of P2Y12 receptors, and may consequently provide more thorough 
anti-thrombotic cover than short-lived thienopyridines.12 
 
Here we compare pharmacokinetically different anti-thrombotic regimens in healthy 
volunteers, and examine their relationship with uninhibited platelets. In a previous in 
vitro study we mimicked the in vivo interaction of differently inhibited platelet populations 
by separately labelling and recombining platelets.10 In this ex vivo study we have for the 
first time directly examined the functionality of reticulated platelets, those most likely to 
be uninhibited, in samples from patients with stable cardiovascular disease and 
receiving DAPT. Finally we describe a mechanism by which newly formed reticulated 
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platelets may promote HTPR and potentially explain the reported increased 










In vitro modelling identifies differential inhibition between thienopyridines and 
ticagrelor 
Drug-free platelets were added to platelets pre-incubated with drug to model the in vitro 
functional consequences of platelet turnover during DAPT treatment comprising 
aspirin+prasugrel or aspirin+ticagrelor. This modelling demonstrated that for samples 
treated with prasugrel active metabolite (PAM) responses to ADP returned with 
increases in the proportion of inhibitor-free platelets. In contrast, aggregatory responses 
remained inhibited in samples treated with ticagrelor (Figure 1A & 1B). Analysis by flow 
cytometry and confocal microscopy of aggregates formed from labelled platelet 
subpopulations indicated that drug-free platelets were over-proportionately recruited to 
the formed aggregates in samples treated with aspirin+PAM. This was evidenced by 
clear clustering of uninhibited platelets at the cores of the formed aggregates. In 
contrast, analysis of samples treated with aspirin+ticagrelor did not show this bias 
(Figure 1C).  Quantitative analyses of aggregate images obtained by confocal 
microscopy demonstrated a significantly bigger core volume when drug-free platelets 
were mixed with aspirin+PAM-treated samples (95±18 µm3) than with aspirin+ticagrelor-
treated samples (24±4 µm3; Figure 1D & 1E). 
 
Ticagrelor but not prasugrel therapy inhibits drug-free platelets upon in vitro 
transfusion  
Having identified pharmacological differences between PAM and ticagrelor in vitro, we 
tested differences between prasugrel and ticagrelor in their ability to inhibit drug-free 
platelets in a larger inhibited environment using an ex vivo approach in healthy 
volunteers who had either taken aspirin+prasugrel or aspirin+ticagrelor for 7 days. 
Blood was collected at estimated peak concentrations of prasugrel active metabolite (30 
minutes after last dose) and ticagrelor (120 minutes after last dose), as well as at 6 
hours after the last dose and PRP was made. Drug-free platelets from healthy 
volunteers were then combined with PRP collected from treated subjects to model 
various rates of platelet turnover, ranging from no turnover (x=0%) to full turnover of 
new platelets (x=100%), and aggregation responses determined. In samples derived 
from volunteers treated with aspirin+prasugrel, responses to ADP recovered as the 
proportion of drug-free platelets was increased, whereas responses remained strongly 
inhibited in samples from volunteers who had received aspirin+ticagrelor (Figure 2A & 
Supplemental Figure II). In aspirin+ticagrelor samples the addition of naïve drug-free 
platelets also produced a smaller increase in the response to AA than in 
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aspirin+prasugrel samples (Figure 2C & Supplemental Figure II).  
 
Following LTA, PRP underwent high-throughput flow cytometric imaging to assess 
aggregate structures. Aggregates (mean=104 per individual sample) were blindly 
assessed for the proportion of drug-free core aggregates relative to total aggregates 
(Figures 2E & Supplemental Figure II). Following stimulation by ADP, aggregates 
formed in PRP derived from volunteers treated with aspirin+prasugrel contained a 
higher proportion of drug-free cores than those formed in PRP derived from volunteers 
treated with aspirin+ticagrelor (Figure 2B). In contrast, no such difference in proportion 
was observed between volunteer groups for aggregates formed following AA stimulation 
(Figure 2D). Further confocal imaging of aggregates from populations comprising 20% 
drug-free and 80% inhibited platelets confirmed in response to ADP the formation of 
platelet aggregates with a core of drug-free platelets in aspirin+prasugrel-treated 
samples, but not in aspirin+ticagrelor-treated samples (Figure 3a). Moreover 
quantitative analysis of these images demonstrated fewer drug-free platelets were 
recruited (relative volumes 0.14±0.02 µm3 vs 0.32±0.04 µm3 respectively p<0.001; 
Figure 3C) and smaller drug-free cores formed (17±3 µm3 vs 70±12 µm3; p<0.001; 
Figure 3D) in aspirin+ticagrelor-treated samples compared to aspirin+prasugrel-treated 
samples. Differences in distribution of platelet subpopulations following stimulation by 
AA were less pronounced (Figure 3B, 3E & 3F) but were similarly observed at ‘plasma 
peak’ time-points (Supplementary Figure III). 
 
Reticulated platelets are more reactive than older platelets and locate to the core 
of aggregates  
To monitor the reactivity of newly formed platelets, also called reticulated platelets due 
to the presence of mRNA, platelets were labelled ex vivo with the nucleic dye, thiazole 
orange (TO).15 We devised a gating strategy (Supplemental Figure IV) to determine 
the proportional usage of these newly formed platelets relative to older non-reticulated 
platelets16 during aggregate formation. Using PRP from untreated healthy volunteers 
stimulated by AA (1 mmol/L) or ADP (20 µmol/L) until 40% of platelets were aggregated 
the relative composition of the non-aggregated platelet population was assessed by flow 
cytometry. Following aggregation there was a significant reduction in the relative 
proportion of reticulated platelets indicating that reticulated platelets contributed over-
proportionately to aggregate formation (Figure 4A & 4B). Subsequent examination of 
formed aggregates by flow cytometric imaging confirmed the presence of reticulated 
platelets in the majority of aggregates (Figure 4C). 
 
Reticulated platelets undermine platelet inhibition by DAPT in patients taking 
thienopyridines but not in patients taking ticagrelor 
Differential effects of thienopyridine- and ticagrelor-mediated inhibition on reticulated 
platelet populations were assessed in patients with established stable coronary artery 
disease who received DAPT comprising either aspirin+clopidogrel or aspirin+ticagrelor. 
Patients were assessed for pharmacological efficacy by testing of platelet reactivity 
using LTA. All patients had a final aggregation to ADP (20 µmol/L) of <43%, with those 
receiving ticagrelor considerably lower (Supplemental Table I). TO stained PRP was 
incubated with vehicle, AA or ADP for 5 min and reticulated proportion of the non-
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aggregated platelets assessed by flow cytometric imaging. In both therapy groups, upon 
stimulation by AA, reticulated platelets disappeared from the non-aggregated platelet 
population; reducing from 10.9±0.3 % to 4.0±0.4 % (p<0.001) in aspirin+clopidogrel 
patient samples and from 11.1±0.5 % to 5.4±0.5 % (p<0.001) in aspirin+ticagrelor 
patient samples (Figures 5A & 5B). This indicated an over-proportional recruitment of 
reticulated platelets into the formed aggregates. In line with above data from AA-
stimulated samples, stimulation by ADP of samples from patients receiving 
aspirin+clopidogrel caused a significant reduction in the relative population of reticulated 
platelets in the non-aggregated population, from 10.9±0.3 % to 5.0±0.6 % (Figure 5B, 
p<0.01). However, in contrast to these observations, stimulation with ADP of PRP from 
patients receiving aspirin+ticagrelor did not result in a drop of the reticulated platelet 
population (11.1±0.5 % to 10.1±0.8 %; Figure 5A, p>0.05).  The absence of a change 
in proportion indicates a proportionally equivalent recruitment of reticulated and non-
reticulated platelets to aggregates. Qualitative analysis of the imaged formed 
aggregates from each patient group demonstrated that in samples from patients 
receiving aspirin+ticagrelor there were few reticulated platelets dispersed throughout the 
aggregate (Figure 5C) whereas in samples from patients receiving aspirin+prasugrel 
there were increased numbers of reticulated platelets primarily located in the core of the 





In our previous study, we demonstrated through in vitro modelling that drug-free 
platelets can act as seeds for aggregate formation during antiplatelet therapy.10  Here 
we have studied the impact of platelet turnover, including the influences of reticulated 
platelets, during standard dual antiplatelet therapy in both healthy volunteers and stable 
cardiovascular patients. Furthermore, we have compared thienopyridines with ticagrelor 
and from our results provide a potential pathophysiological mechanism that unites 
previous, but separate, associations between differential effectiveness of P2Y12 receptor 
inhibition, HTPR, immature platelet counts and thrombotic risk.3, 6, 13, 14 We directly 
demonstrate that following stimulation reticulated platelets are over-proportionately 
recruited to aggregates where they can act as seeds for larger aggregate formation and 
by interplay with drug pharmacokinetics provide a causative mechanism for observed 
HTPR. 
 
Key to explaining our observations is an understanding that the formation of a drug-free, 
uninhibited, subpopulation of platelets during DAPT occurs as a result of platelet 
turnover and drug pharmacokinetics. In terms of standard therapy, aspirin is a short-
lived but irreversible inhibitor of platelet COX-1. Similarly, the thienopyridines, prasugrel 
or clopidogrel acting through their active metabolites, are pharmacokinetically short-
lived and irreversible antagonists of platelet P2Y12 receptors. When used as DAPT this 
combination of aspirin plus thienopyridine produces inhibition of circulating platelets. 
However, as we model in vitro and demonstrate ex vivo, neither aspirin nor prasugrel 
(or prasugrel active metabolite) appears present in circulating blood at sufficient levels 
to inhibit the responses of exogenous platelets added in vitro. One potential explanation 
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for this observation is that these drugs are present in effective inhibitory concentrations 
only within the portal circulation and so inhibit platelets as they pass through, as has 
been suggested for aspirin for over 30 years.17 This would explain also why platelets 
newly released from the bone marrow are either poorly, or not, inhibited by aspirin and 
thienopyridines.18, 19 One should not overlook, however, the alternative explanation that 
because of their short half-lives within the circulating blood the active forms of 
thienopyridines may have insufficient time to interact with exogenously added platelets 
in our test system. In contrast, as expected, ticagrelor as a longer lasting (plasma half-
life of about 8 hours) direct acting reversible antagonist of P2Y12 receptors 12 inhibited 
the responses to ADP of exogenously added platelets.  
 
As well as modelling these interactions with regard to standard tests of platelet 
reactivity4, our imaging techniques demonstrated that exogenously added uninhibited 
platelets were clustered at the cores of aggregates formed in response to ADP in 
samples from volunteers receiving aspirin+clopidogrel, consistent with their ability to act 
as seeds for aggregate formation. As previously hypothesised12 the longer half-life and 
reversible binding of ticagrelor, in contrast to the irreversible binding of prasugrel, 
means it is present and able to act upon the exogenous drug-free, uninhibited, platelet 
subpopulation. It can be noted that ticagrelor might in addition act pleiotropically upon 
adenosine uptake to influence platelet function20, 21, but we did not test this possibility.  It 
was notable that the recovery of the response to AA caused by the addition of 
exogenous drug-free platelets was blunted in samples prepared from individuals 
receiving aspirin+ticagrelor compared to those receiving aspirin+prasugrel. This is 
consistent with P2Y12 blockade reducing the amplifying effects of TxA2 produced in 
response to AA22-26, and confirmed our in vitro observation that circulating ticagrelor, 
unlike prasugrel, may provide additional compensation for the loss of COX-1 inhibition 
noted in individuals with elevated platelet turnover 26, 27. 
 
In our in vitro and ex vivo models we stained or labelled un-inhibited platelets to allow 
determination of their function as a subpopulation.  Examination of the definitive drug-
free population in patients is less straightforward.  Newly formed immature platelets are 
also called reticulated platelets due to the presence of residual cytosolic mRNA. Dyes 
such as TO, which stain nucleic acids, are routinely used for determining the 
percentage of reticulocytes (including platelets) in blood samples.28 Accepting that the 
emergence of a drug-free platelet subpopulation occurs as a result of platelet turnover 
and the associated release of newly formed platelets, analyses of newly formed 
platelets in samples can be used to inform on the behaviour of drug-free platelets. We 
have demonstrated under our particular conditions that TO staining of PRP identifies 
those platelets with the highest mRNA content. We therefore utilised this approach to 
track newly formed platelets during aggregate formation. In samples from healthy 
volunteers not taking anti-platelet drugs reticulated platelets were over-proportionally 
recruited to the formation of aggregates, indicating that under normal physiological 
conditions they are important drivers of the aggregation process. This finding concurs 
with previous reports by ourselves, and others, that newly formed reticulated platelets 




Finally, we sought to determine whether such a mechanism was also present in patient 
samples. We recruited patients with established, stable coronary artery disease taking 
clopidogrel or ticagrelor plus aspirin, and confirmed drug efficacy to ensure patients 
exhibiting HTPR were not included in our analyses. As in our in vitro and ex vivo 
modelling, the behaviour of reticulated platelets matched that of uninhibited platelets. In 
samples taken from patients receiving aspirin+clopidogrel there was a significant loss in 
the proportion of reticulated platelets from the non-aggregated single platelet population 
following ADP stimulation, whereas strikingly, in patients receiving aspirin & ticagrelor 
no proportional change was observed. Similarly, examination of the formed aggregates 
revealed that in response to ADP reticulated platelets were clustered in the core and 
present in greater proportion in samples from patients receiving clopidogrel+aspirin than 
in samples from patients receiving ticagrelor+aspirin.  
 
Our results support a mechanism through which newly formed uninhibited reticulated 
platelets play a key role in the limiting the effectiveness of particular antiplatelet 
therapies. Furthermore, we provide functional evidence and unique images 
substantiating the observed impact of subpopulations of reticulated drug-free platelets 
on the formation of platelet aggregates under recommended clinical testing settings.30, 31 
Together these are consistent with emerging evidence establishing a link between 
reticulated platelets and platelet responsiveness to short-lived P2Y12 antagonist 
(thienopyridines)11, 32 but not ticagrelor.33 Whilst there have been recent indications of 
similar short-term efficacy for prasugrel and ticagrelor in patients with acute myocardial 
infarction34, no comparisons or sub-group analyses has yet been conducted in 
conditions of high platelet turnover.  Moreover our data suggests that in vivo the use of 
ticagrelor rather than clopidogrel or prasugrel may mitigate incomplete inhibition of TXA2 
formation by prophylactic aspirin4, consistent with our previous reports regarding the 
importance of P2Y12 receptors in amplifying responses to platelet produced TXA2.35-38 
 
In conclusion, we demonstrate a functional mechanism for newly formed reticulated 
platelets to drive thrombus formation even during standard DAPT. Furthermore our 
study demonstrates that ticagrelor may be more efficacious than thienopyridine 
(prasugrel or clopidogrel) therapy for mitigating HTPR associated with the generation of 
new platelets during standard anti-thrombotic regimens. In turn this illustrates the 
importance of considering platelet turnover and the pharmacological inhibition of the 
reticulated platelet subpopulation in attaining optimal anti-thrombotic potential. Finally 
given the central role for platelet turnover in our model, patients with conditions such as 
diabetes and chronic kidney disease, where increased platelet turnover has been 
identified or suspected, may particularly benefit from such considerations. 
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1 We demonstrate a functional mechanism by which newly formed reticulated platelets 
can drive thrombus formation even during standard DAPT. 
 
2 Study reveals underlying reasons to consider platelet turnover and drug 
pharmacokinetics in the selection of appropriate antiplatelet therapies for optimal anti-
thrombotic protection. 
 
Figure Legends:  
 
Figure 1. Ticagrelor reduces aggregation and prevents formation of drug-free platelet 
cores during aggregate formation in vitro. PRP derived from blood pre-incubated with aspirin 
(30µM) and PAM (3µM) or ticagrelor (1.35µM) was mixed in a range of proportions with PRP 
from blood pre-incubated with respective vehicles or with ticagrelor (1.35µM) to reflect mid-dose 
t=6hour levels. Aggregation in response to (A) ADP 20µM or (B) AA 1mM was determined by 
LTA. Data presented as mean±SEM and compared by two-way ANOVA (n=4, **p<0.01, 
***p<0.001). (C) Multiple images captured by ImageStreamX of aggregates (mixtures of 85% 
aspirin+PAM-pretreated platelets or aspirin+ticagrelor pretreated platelets plus 15% uninhibited 
platelets). Each panel contains columns with following image sets: drug-free (green), inhibited 
platelets (red), merged image. (D) Representative confocal images of aggregates (left) formed 
from mixtures comprising 85% aspirin+PAM-pretreated platelets or aspirin+ticagrelor-pretreated 
(green) and 15% uninhibited platelets (red). (E) Images were analysed for size of the uninhibited 
platelet particles. Data is presented as mean±SEM and compared by t-test (n=4, **p<0.01). 
 
Figure 2. Drug-free platelets restore ex vivo aggregation responses differentially in 
presence of prasugrel or ticagrelor. PRP isolated from individuals 6h after receiving 
aspirin+prasugrel or aspirin+ticagrelor was mixed with increasing proportions of drug-free 
platelets and then stimulated. Final aggregation of samples stimulated with (A) ADP (20 µM) or 
(C) arachidonic acid (1 mM). (B, D) Aggregates (%) where cores comprise naïve platelets were 
blind scored and calculated from flow cytometric images of platelet aggregates from 
corresponding samples. 104 aggregates assessed per individual sample, with data presented 
as mean±SEM and compared by two-way ANOVA (n=10 samples, *p<0.05, **p<0.01, 
***p<0.001). (E) Representative flow cytometric imaging (x60 objective) of aggregates formed in 
response to ADP (20µM) from 80%:20% mixtures of aspirin+prasugrel-inhibited PRP or 
aspirin+ticagrelor-inhibited PRP obtained 6 hours after the last drug dose was administered 
(red) and drug-free platelets (green).  Scale bars equal to 7µm. 
 
Figure 3. Drug-free platelets form cores within aggregates in presence of prasugrel but 
not ticagrelor. Representative confocal images of (A) ADP-stimulated or (B) AA-stimulated 
aggregates formed from 80%:20% mixtures of aspirin+prasugrel-inhibited PRP or 
aspirin+ticagrelor-inhibited PRP obtained 6 hours after the last drug dose was administered 
(red) and drug-free platelets (green), conditions as in Figure 2. Images were analysed for (C, E) 
volume of the drug free platelet particles relative to the total aggregate volume and (D, F) 
average size of drug-free platelet clusters. Scale bars represent 5 µm. Data is presented as 
mean±SEM and compared by t-test (n=7-10; *p<0.05, ***p<0.001). 
 
Figure 4. Reticulated platelets display elevated reactivity in response to both arachidonic 
acid and ADP. The proportion of reticulated platelets among non-aggregated platelets was 
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assessed by flow cytometry in platelet rich plasma incubated with vehicle, (A) arachidonic acid, 
or (B) ADP.  (C) Representative flow cytometric images of non-reticulated and reticulated 
(mRNA stain green) single platelets (red), as well as aggregates formed in response to ADP. 
Scale bars equal to 7µm. Data presented as individual data points with overlaid mean±SEM and 
compared by paired t-test (n=6; *p<0.05, ***p<0.001). 
 
Figure 5. In patients the response of reticulated platelets to ADP is inhibited to a greater 
extent by ticagrelor than by clopidogrel. The reticulated platelet subpopulation among non-
aggregated single platelets was assessed by flow cytometry in PRP incubated with vehicle, 
ADP, or arachidonic acid. Samples were obtained from patients taking (A) ticagrelor or (B) 
clopidogrel (in addition to aspirin). Representative flow cytometric images of ADP-stimulated 
platelet aggregates (platelets red; mRNA green) formed in samples from patients taking aspirin 
plus (C) ticagrelor or (D) clopidogrel. Scale bars equal to 7µm. Data presented as individual 
data points with overlaid mean±SEM and compared by paired t-test (n=9-10; ***p<0.001). 
 
 
 
